YAP1 and neuroblastoma: While mutations in negative YAP regulators such as PTPN14 in relapsed neuroblastomas can lead to upregulated YAP transcriptional activity at relapse [9], not all YAP-expressing neuroblastomas harbor PTPN14 mutations and the exact mechanism as to how YAP induces therapy resistance in neuroblastoma may be context-dependent based on the type of chemotherapy or targeted therapy used [71,72].